Tag: FGFR inhibitor therapy

Home / FGFR inhibitor therapy

Categories

Erdafitinib is approved by USFDA for locally advanced or metastatic urothelial carcinoma

Erdafitinib (Balversa, Janssen Biotech) was approved by the Food and Drug Administration on January 19, 2024, for adult patients with FGFR3 genetic changes who have locally advanced or metastatic uro...
fgfr-inhibitor-therapy

Scan the code